Clinical trials: Squamous Cell Cancer
Carcinoma, Squamous Cell of Head and Neck
Biomarker-based Study in R/M SCCHN
This is a biomarker-driven trial that will enroll patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing after first-line platinum-based chemotherapy.
- Trial name
- UPSTREAM (NCT03088059)
- Testing
- Afatinib, Palbociclib, standard of care
- Where
- 36 sites in Belgium, France and 3 more
- Volunteers
- 340 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Gene Mutations
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
This is a prospective, open-label, multi-center, single-arm clinical trial
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Gene Mutations, Brain Metastasis
- Trial name
- NCT07343479
- Testing
- sac-TMT plus EGFR-TKI
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Zhejiang Cancer Hospital
Non-squamous Non-Small Cell Lung Cancer
Apatinib in Advanced Non-squamous，NSCLC
To explore the efficacy and safety of apatinib in non-squamous non-small cell lung cancer in the real-world.
- Trial name
- NCT03376191
- Testing
- apatinib
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jian Fang
Advanced Solid Tumor, Esophageal Squamous Cell Carcinoma
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
To evaluate the safety and tolerability of JAB-3068 administered in investigational regimens in adult participants with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Esophageal Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04721223
- Testing
- JAB-3068, PD1 inhibitor
- Where
- 3 sites in China
- Volunteers
- 12 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Advanced or Metastatic Solid Tumors, Lung Cancer
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03665285
- Testing
- NC318
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- NextCure, Inc.
Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
This phase II trial compares the effect of chemotherapy (carboplatin and paclitaxel) with versus without cemiplimab given before surgery (neoadjuvant) in patients with sinonasal squamous cell cancer.
- Conditions
- Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Sinonasal Cancer AJCC v8
- Trial name
- NCT07281417
- Testing
- Biopsy Procedure, Biospecimen Collection, Carboplatin
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer
This study is being done to determine the overall progression-free survival (PFS) in patients with advanced or metastatic (Stage IIIB - pleural effusion/IV), non-squamous histology NSCLC treated with metronomic chemotherapy plus…
- Trial name
- NCT00655850
- Testing
- Paclitaxel, Gemcitabine, Avastin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Alabama at Birmingham
Head and Neck Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00352118
- Testing
- filgrastim, pegfilgrastim, cisplatin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Squamous Cell Carcinoma of the Skin
Preventing Squamous Cell Skin Cancer
This study is proposed based on our work showing that the diabetes drug Pioglitazone strongly inhibits growth of tissue cultured squamous cell carcinoma (SCC) of the skin.
- Trial name
- NCT02347813
- Testing
- Pioglitazone
- Volunteers
- 12 people
- Sponsor
- University of Rochester
Cervical Cancer
Preservation of Ovarian Function Via LOT in Squamous Cell Carcinoma of the Cervix
The purpose of this study is to evaluate the feasibility, safety and efficacy of laparoscopic ovarian transposition in women less than 40 years of age with locally advanced cervical squamous cell carcinoma
- Trial name
- NCT00204997
- Testing
- Laparoscopic ovarian transposition
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Wisconsin, Madison
Head and Neck Cancer
InGReS: Intra-treatment Image Guided Adaptive Radiotherapy Dose-escalation Study
InGReS is a phase I pilot study of adaptive dose-escalated radiotherapy in combination with platinum-based chemotherapy (CRT) for locally advanced head and neck cancer.
- Trial name
- InGReS (NCT05393297)
- Testing
- Imaging: Intra-treatment FDG-PET-CT and MRI, Intra-treatment Image-Guided Adaptive Radiotherapy Dose-escalation
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Drug Safety ; Drug Specificity
Cetuximab - IRDye800 Intraoperative Fluorescence Imaging in Esophagectomy of Esophageal Cancer
The esophageal squamous cell carcinoma (ESCC) has high prevalence and mortality in China, which become a severe challenge for public health.
- Trial name
- NCT04161560
- Testing
- Cetuximab-IRDye800
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Esophagus Cancer, Stage III
GASC1 Inhibitor Caffeic Acid for Squamous Esophageal Cell Cancer (ESCC)
Caffeic acid can target inhibit GASC1 (gene amplified in squamous cell carcinoma 1, also known as KDM4C and JMJD2C) expression and GASC1 is confirmed to be a new oncogene in several cancers including esophageal cancer.
- Trial name
- GiCAEC (NCT04648917)
- Testing
- Caffeic acid
- Where
- 3 sites in China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Squamous Cell Carcinoma of the Skin
Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin
This study intends to conduct a single-arm, prospective and open clinical study, using carrellizumab combined with albumin-binding paclitaxel regimen for first-line treatment of squamous cell carcinoma of the skin, including 24…
- Trial name
- NCT05886140
- Testing
- Carrilizumab with albumin-binding paclitaxel
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Henan Cancer Hospital
Head and Neck Cancer
Anti-platelet + Pembro for H&N Tumors
The purpose of this study is to see if anti-platelet therapy combined with anti-PD-1 immunotherapy can cause a more favorable immunologic response thatn with immunotherapy alone in patients with recurrent or metastatic squamous…
- Trial name
- NCT03245489
- Testing
- Pembrolizumab, Clopidogrel, acetylsalicylic acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical University of South Carolina
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may…
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma
- Trial name
- NCT02834013
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 1,007 sites in United States, Guam
- Volunteers
- 798 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer, Bladder Cancer
Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies
The purpose of the study is to determine to evaluate safety and tolerability of CPL304110 when administered once daily to adults with advanced solid malignancies.
- Conditions
- Gastric Cancer, Bladder Cancer, Squamous Non-small Cell Lung Cancer, Cholangiocarcinoma
- Trial name
- NCT04149691
- Testing
- CPL304110
- Where
- 7 sites in Poland
- Volunteers
- 42 people
- Sponsor
- Celon Pharma SA
Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC)
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety…
- Conditions
- Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma
- Trial name
- LB-LR1109 (NCT06332755)
- Testing
- Phase 1a: LB-LR1109, Phase 1b: LB-LR1109 and Atezolizumab
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- LG Chem
Locally Advanced Head and Neck Squamous Cell Carcinoma
Low-Dose Weekly vs High-Dose Cisplatin
This study is a prospective open-label randomized clinical trial. Following informed consent eligible LASCCHN patients (n=100) planned for CRT will be stratified by tumor p16 status and then randomized in a 1:1 fashion to either…
- Trial name
- RADIO (NCT03649048)
- Testing
- High-Dose Cisplatin, Low-Dose Cisplatin, Radiotherapy
- Where
- 3 sites in Canada
- Volunteers
- 100 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Head and Neck Cancer
Studying Biomarkers in Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on E1302 Trial
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01619618
- Testing
- mutation analysis, polymerase chain reaction, polymorphism analysis
- Volunteers
- 183 people
- Sponsor
- Eastern Cooperative Oncology Group